DermTech Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.99
- Today's High:
- $2.14
- Open Price:
- $2.1
- 52W Low:
- $1.55
- 52W High:
- $8.93
- Prev. Close:
- $2.1
- Volume:
- 110529
Company Statistics
- Market Cap.:
- $77.41 million
- Book Value:
- 3.45
- Revenue TTM:
- $14.28 million
- Operating Margin TTM:
- -840.65%
- Gross Profit TTM:
- $647000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -36.01%
- Return on Equity TTM:
- -75.85%
Company Profile
DermTech Inc had its IPO on 2017-08-10 under the ticker symbol DMTK.
The company operates in the Healthcare sector and Diagnostics & Research industry. DermTech Inc has a staff strength of 278 employees.
Stock update
Shares of DermTech Inc opened at $2.1 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.99 - $2.14, and closed at $1.99.
This is a -5.24% slip from the previous day's closing price.
A total volume of 110,529 shares were traded at the close of the day’s session.
In the last one week, shares of DermTech Inc have slipped by -11.95%.
DermTech Inc's Key Ratios
DermTech Inc has a market cap of $77.41 million, indicating a price to book ratio of 0.4347 and a price to sales ratio of 4.3608.
In the last 12-months DermTech Inc’s revenue was $14.28 million with a gross profit of $647000 and an EBITDA of $-118291000. The EBITDA ratio measures DermTech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, DermTech Inc’s operating margin was -840.65% while its return on assets stood at -36.01% with a return of equity of -75.85%.
In Q1, DermTech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 6.5%.
DermTech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into DermTech Inc’s profitability.
DermTech Inc stock is trading at a EV to sales ratio of 0.1103 and a EV to EBITDA ratio of 0.5179. Its price to sales ratio in the trailing 12-months stood at 4.3608.
DermTech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $177.12 million
- Total Liabilities
- $16.14 million
- Operating Cash Flow
- $-8194000.00
- Capital Expenditure
- $757000
- Dividend Payout Ratio
- 0%
DermTech Inc ended 2024 with $177.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $177.12 million while shareholder equity stood at $107.24 million.
DermTech Inc ended 2024 with $0 in deferred long-term liabilities, $16.14 million in other current liabilities, 3000.00 in common stock, $-354317000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.44 million and cash and short-term investments were $104.78 million. The company’s total short-term debt was $1,853,000 while long-term debt stood at $0.
DermTech Inc’s total current assets stands at $112.39 million while long-term investments were $0 and short-term investments were $56.34 million. Its net receivables were $3.69 million compared to accounts payable of $1.68 million and inventory worth $1.57 million.
In 2024, DermTech Inc's operating cash flow was $-8194000.00 while its capital expenditure stood at $757000.
Comparatively, DermTech Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.99
- 52-Week High
- $8.93
- 52-Week Low
- $1.55
- Analyst Target Price
- $5.1
DermTech Inc stock is currently trading at $1.99 per share. It touched a 52-week high of $8.93 and a 52-week low of $8.93. Analysts tracking the stock have a 12-month average target price of $5.1.
Its 50-day moving average was $2.72 and 200-day moving average was $3.19 The short ratio stood at 5.3 indicating a short percent outstanding of 0%.
Around 414.6% of the company’s stock are held by insiders while 2756.3% are held by institutions.
Frequently Asked Questions About DermTech Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.